Lilly Looks To Volume-Driven Growth In Decade Ahead
Executive Summary
CEO Dave Ricks told investors Lilly will succeed via volume-driven growth of nine key products launched since 2019, which its commitment to lower prices will facilitate.
You may also be interested in...
Lilly Revenue Guidance Rises Along With Diabetes, Obesity Investments
Lilly will increase spending, resulting in lower-than-expected EPS, to drive its revenue growth, relying on sales of new products, particularly its next generation of incretin agonists for diabetes and obesity.
As Lilly’s Realized Sales Prices Drop, Ricks Reiterates Criticism Of US Drug Price Plan
With Lilly’s sales narrative hampered by global price pressures, Lilly CEO David Ricks again criticized drug price negotiation proposals before Congress. Mounjaro launch offers a bright spot, exceeding projections.
Lilly’s Mounjaro Diabetes Approval Is First Challenge To Novo’s GLP-1 Franchise
The GLP-1/GIP agonist tirzepatide is a key addition to Lilly’s commercial portfolio as the company leans on new products to deliver on volume-driven growth through the current decade.